Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.50
JNJ's Cash to Debt is ranked higher than
50% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. JNJ: 1.50 )
Ranked among companies with meaningful Cash to Debt only.
JNJ' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 1.63 Max: 6.28
Current: 1.5
0.46
6.28
Equity to Asset 0.52
JNJ's Equity to Asset is ranked lower than
68% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. JNJ: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
JNJ' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.67
Current: 0.52
0.5
0.67
Interest Coverage 28.02
JNJ's Interest Coverage is ranked lower than
63% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.94 vs. JNJ: 28.02 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.02  Med: 36.85 Max: 208.73
Current: 28.02
28.02
208.73
F-Score: 8
Z-Score: 5.17
M-Score: -2.49
WACC vs ROIC
7.09%
28.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 27.48
JNJ's Operating margin (%) is ranked higher than
90% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.61 vs. JNJ: 27.48 )
Ranked among companies with meaningful Operating margin (%) only.
JNJ' s Operating margin (%) Range Over the Past 10 Years
Min: 22.36  Med: 25.43 Max: 28.2
Current: 27.48
22.36
28.2
Net-margin (%) 22.04
JNJ's Net-margin (%) is ranked higher than
88% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. JNJ: 22.04 )
Ranked among companies with meaningful Net-margin (%) only.
JNJ' s Net-margin (%) Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 22.04
Current: 22.04
14.87
22.04
ROE (%) 21.88
JNJ's ROE (%) is ranked higher than
86% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. JNJ: 21.88 )
Ranked among companies with meaningful ROE (%) only.
JNJ' s ROE (%) Range Over the Past 10 Years
Min: 17.02  Med: 23.79 Max: 30.17
Current: 21.88
17.02
30.17
ROA (%) 11.55
JNJ's ROA (%) is ranked higher than
82% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. JNJ: 11.55 )
Ranked among companies with meaningful ROA (%) only.
JNJ' s ROA (%) Range Over the Past 10 Years
Min: 8.93  Med: 12.96 Max: 17.08
Current: 11.55
8.93
17.08
ROC (Joel Greenblatt) (%) 101.70
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.31 vs. JNJ: 101.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
JNJ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 114.87
Current: 101.7
65.66
114.87
Revenue Growth (3Y)(%) 1.40
JNJ's Revenue Growth (3Y)(%) is ranked lower than
63% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. JNJ: 1.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
JNJ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.4  Med: 7.2 Max: 14.8
Current: 1.4
1.4
14.8
EBITDA Growth (3Y)(%) 9.30
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. JNJ: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
JNJ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.6  Med: 10 Max: 16.7
Current: 9.3
-6.6
16.7
EPS Growth (3Y)(%) 12.40
JNJ's EPS Growth (3Y)(%) is ranked higher than
58% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. JNJ: 12.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
JNJ' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 10.9 Max: 20.2
Current: 12.4
-8.6
20.2
GuruFocus has detected 4 Warning Signs with Johnson & Johnson $JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JNJ's 10-Y Financials

Financials (Next Earnings Date: 2017-01-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

JNJ Guru Trades in Q1 2016

David Rolfe 5,250 sh (New)
Jim Chanos 29,730 sh (New)
Diamond Hill Capital 1,969 sh (New)
John Burbank 1,583,456 sh (+2203.04%)
Joel Greenblatt 242,043 sh (+511.44%)
Jim Simons 2,380,600 sh (+263.28%)
Murray Stahl 30,774 sh (+2.78%)
John Rogers 850,915 sh (+2.31%)
Mario Gabelli 337,588 sh (+1.60%)
Tom Gayner 610,800 sh (+0.93%)
Richard Pzena 1,185,329 sh (+0.92%)
Ken Fisher 10,854,263 sh (+0.35%)
Mairs and Power 2,185,213 sh (+0.04%)
Jim Chanos 5,952 sh (unchged)
Richard Snow 3,260 sh (unchged)
Chuck Royce 9,000 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Richard Perry 292,729 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Michael Price 25,000 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
Ray Dalio Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,327,465 sh (-0.10%)
Jeff Auxier 105,176 sh (-0.24%)
Dodge & Cox 34,808 sh (-1.77%)
Charles Brandes 146,253 sh (-3.20%)
John Buckingham 63,638 sh (-3.21%)
Donald Yacktman 7,080,500 sh (-3.22%)
Pioneer Investments 3,675,335 sh (-3.89%)
John Hussman 25,000 sh (-5.03%)
Manning & Napier Advisors, Inc 3,543,252 sh (-6.01%)
Yacktman Focused Fund 2,300,000 sh (-8.00%)
Tweedy Browne 3,383,445 sh (-8.39%)
Sarah Ketterer 1,364,323 sh (-8.88%)
Jeremy Grantham 9,036,395 sh (-9.37%)
RS Investment Management 8,397 sh (-12.46%)
T Rowe Price Equity Income Fund 3,961,300 sh (-15.23%)
Robert Olstein 50,000 sh (-29.58%)
First Eagle Investment 1,142,872 sh (-62.31%)
Paul Tudor Jones 15,876 sh (-65.85%)
PRIMECAP Management 3,023,678 sh (-71.32%)
Ruane Cunniff 13,925 sh (-78.50%)
» More
Q2 2016

JNJ Guru Trades in Q2 2016

Louis Moore Bacon 3,552 sh (New)
Ray Dalio 129,700 sh (New)
John Paulson 128,000 sh (New)
Tom Russo 2,050 sh (New)
Lee Ainslie 28,230 sh (New)
Jim Chanos 49,843 sh (+67.65%)
RS Investment Management 10,007 sh (+19.17%)
Jeremy Grantham 9,741,420 sh (+7.80%)
Diamond Hill Capital 2,110 sh (+7.16%)
Dodge & Cox 35,185 sh (+1.08%)
John Rogers 857,563 sh (+0.78%)
John Buckingham 63,881 sh (+0.38%)
Mairs and Power 2,185,819 sh (+0.03%)
Prem Watsa 82,850 sh (unchged)
Michael Price 25,000 sh (unchged)
John Hussman 25,000 sh (unchged)
David Carlson 460,000 sh (unchged)
David Rolfe 5,250 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Richard Perry 292,729 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,600,000 sh (unchged)
John Burbank Sold Out
Chuck Royce Sold Out
Jeff Auxier 105,126 sh (-0.05%)
Ken Fisher 10,845,150 sh (-0.08%)
Murray Stahl 30,622 sh (-0.49%)
Richard Snow 3,220 sh (-1.23%)
Paul Tudor Jones 15,553 sh (-2.03%)
Tweedy Browne 3,216,513 sh (-4.93%)
Donald Yacktman 6,671,349 sh (-5.78%)
PRIMECAP Management 2,830,937 sh (-6.37%)
Manning & Napier Advisors, Inc 3,297,804 sh (-6.93%)
Richard Pzena 1,103,032 sh (-6.94%)
Ruane Cunniff 12,933 sh (-7.12%)
Mario Gabelli 312,831 sh (-7.33%)
Charles Brandes 133,128 sh (-8.97%)
Pioneer Investments 3,223,857 sh (-12.28%)
Barrow, Hanley, Mewhinney & Strauss 13,210,591 sh (-13.81%)
T Rowe Price Equity Income Fund 3,400,000 sh (-14.17%)
Yacktman Focused Fund 1,950,000 sh (-15.22%)
Robert Olstein 41,000 sh (-18.00%)
First Eagle Investment 759,790 sh (-33.52%)
Sarah Ketterer 787,234 sh (-42.30%)
Jim Simons 626,100 sh (-73.70%)
Joel Greenblatt 4,906 sh (-97.97%)
» More
Q3 2016

JNJ Guru Trades in Q3 2016

Samuel Isaly 450,936 sh (New)
Joel Greenblatt 214,043 sh (+4262.88%)
Jim Simons 1,475,100 sh (+135.60%)
Paul Tudor Jones 28,124 sh (+80.83%)
Diamond Hill Capital 2,296 sh (+8.82%)
Pioneer Investments 3,454,669 sh (+7.16%)
John Rogers 858,549 sh (+0.11%)
John Hussman 25,000 sh (unchged)
David Rolfe 5,250 sh (unchged)
David Carlson 460,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Prem Watsa 82,850 sh (unchged)
Ken Fisher 10,845,620 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Richard Perry Sold Out
Tom Russo Sold Out
Richard Snow 3,215 sh (-0.16%)
Dodge & Cox 34,985 sh (-0.57%)
T Rowe Price Equity Income Fund 3,380,000 sh (-0.59%)
Jeff Auxier 104,176 sh (-0.90%)
Mairs and Power 2,153,237 sh (-1.49%)
John Buckingham 62,429 sh (-2.27%)
Charles Brandes 126,627 sh (-4.88%)
Mario Gabelli 294,127 sh (-5.98%)
Murray Stahl 28,648 sh (-6.45%)
Barrow, Hanley, Mewhinney & Strauss 12,334,416 sh (-6.63%)
Lee Ainslie 26,320 sh (-6.77%)
Tweedy Browne 2,978,783 sh (-7.39%)
Yacktman Focused Fund 1,800,000 sh (-7.69%)
Donald Yacktman 6,143,753 sh (-7.91%)
Manning & Napier Advisors, Inc 3,028,532 sh (-8.17%)
Richard Pzena 1,002,314 sh (-9.13%)
Sarah Ketterer 705,335 sh (-10.40%)
PRIMECAP Management 2,519,397 sh (-11.00%)
Yacktman Fund 3,200,000 sh (-11.11%)
Louis Moore Bacon 2,875 sh (-19.06%)
Michael Price 20,000 sh (-20.00%)
Jeremy Grantham 7,282,964 sh (-25.24%)
Robert Olstein 30,000 sh (-26.83%)
Jim Chanos 35,387 sh (-29.00%)
Ruane Cunniff 5,713 sh (-55.83%)
Ray Dalio 44,400 sh (-65.77%)
John Paulson 35,000 sh (-72.66%)
First Eagle Investment 28,177 sh (-96.29%)
» More
Q4 2016

JNJ Guru Trades in Q4 2016

Ken Fisher 10,957,134 sh (+1.03%)
Yacktman Focused Fund 1,800,000 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 3,370,000 sh (-0.30%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, NYSE:MRK, NYSE:NVS, NYSE:SNY, NYSE:ABBV, OTCPK:GLAXF, OTCPK:BAYZF, NYSE:LLY, NYSE:BMY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF » details
Traded in other countries:JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. Baby Care includes the JOHNSON'S line of products. Oral Care includes the LISTERINE product line. Brands in Skin Care include the AVEENO; CLEAN & CLEAR; DABAO; JOHNSON'S Adult; LE PETITE MARSEILLAIS; LUBRIDERM; NEUTROGENA; and RoC product lines. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; and the PEPCID line of heartburn products. Brands in Women's Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold both to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia), oncology (e.g., prostate cancer, hematologic malignancies and lung cancer), and cardiovascular and metabolic diseases (e.g., thrombosis and diabetes). Products in this segment are distributed directly to retailers, wholesalers, hospitals and health care professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis, and for adolescents with moderate to severe psoriasis; OLYSIO/SOVRIAD(simeprevir), for combination treatment of chronic hepatitis C in adult patients; PREZISTA (darunavir), EDURANT (rilpivirine), and PREZCOBIX/REZOLSTA. The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care

Guru Investment Theses on Johnson & Johnson

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Top Ranked Articles about Johnson & Johnson

Health Care Companies Showing Good Defensive Potential Deep analysis of historical financial trends for health care companies
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson (NYSE:JNJ), Biogen Inc. (NASDAQ:BIIB) and VCA Inc. (NASDAQ:WOOF), generally had strong financial strength and gross margins. Read more...
Donald Yacktman Reduces Multiple Positions in 3rd Quarter An overview of the guru's largest sales of the quarter
Donald Yacktman (Trades, Portfolio) founded Yacktman Asset Management in 1992. His son, Stephen Yacktman, now primarily runs the firm. During the third quarter, the guru reduced his position in the following stocks: Read more...
Tweedy Browne Sells Halliburton, Johnson & Johnson An overview of the fund's largest trades in the 3rd quarter
Tweedy Browne is an investment partnership owned by its four managing directors, William H. Browne, John D. Spears, Thomas H. Shrager and Robert Q. Wyckoff Jr. During the third quarter the guru firm's largest sales were: Read more...
Samuel Isaly Makes 9 New Buys in 3rd Quarter 5 acquisitions have impacts greater than 2% on portfolio
Samuel Isaly (Trades, Portfolio) of Eaton Vance Worldwide Health Sciences Fund acquired nine new holdings in the third quarter ended Aug. 31. Five of the holdings had impacts greater than 2% on the portfolio. Read more...
What Rate of Return Will an Investment in Johnson & Johnson Deliver? Part 2 Further analysis of J&J's rate of return
Introduction Read more...
Valuation Is a Measurement of Soundness and Not the Primary Total Return Producer: Part 1 Analysis of Consolidated Edison, Johnson & Johnson and Cisco
Introduction Read more...
Ariel Funds Comments on Johnson & Johnson Guru stock highlight
Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward. Read more...
The 5 Most-Sold Stocks of All US Investment Funds Apple, Microsoft top list
Hedge funds have struggled to outperform the market in 2016. According to the Barclay Hedge Fund Index, the average net return for hedge funds year to date is 3.43%, compared to 6.1% for the S&P 500. Read more...
Is Johnson & Johnson Backing Away From a Growing Medical Devices Market? J&J’s medical devices business is on the decline while the overall market is expanding
Johnson & Johnson (NYSE:JNJ) is a very different company now compared to what it was 10 years ago. For starters, at one point Warren Buffett (Trades, Portfolio) was the fourth largest investor in the company, but that is no longer true. J&J has pushed hard into the pharmaceutical segment, while the medical devices segment did not perform well and consumer goods is just not attractive anymore. The company continues to say it is a well-diversified company, but in reality, it has diversified income streams with a major focus on future revenues from the pharmaceutical segment. Read more...
Johnson & Johnson Is Currently Overvalued How Johnson & Johnson fares in the ModernGraham valuation model
Benjamin Graham taught that intelligent investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk. This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company, or by reviewing the 10 Companies Benjamin Graham Would Invest In Today - July 2016. By using the ModernGraham method, one can review a company's historical accomplishments and determine an intrinsic value that can be compared across industries. What follows is a stock analysis showing a specific look at how Johnson & Johnson (NYSE:JNJ) fares in the ModernGraham valuation model. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.20
JNJ's P/E(ttm) is ranked higher than
68% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. JNJ: 20.20 )
Ranked among companies with meaningful P/E(ttm) only.
JNJ' s P/E(ttm) Range Over the Past 10 Years
Min: 10.5  Med: 17.65 Max: 24
Current: 20.2
10.5
24
Forward P/E 16.00
JNJ's Forward P/E is ranked higher than
51% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.95 vs. JNJ: 16.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.20
JNJ's PE(NRI) is ranked higher than
67% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. JNJ: 20.20 )
Ranked among companies with meaningful PE(NRI) only.
JNJ' s PE(NRI) Range Over the Past 10 Years
Min: 10.5  Med: 17.65 Max: 24
Current: 20.2
10.5
24
Price/Owner Earnings (ttm) 22.31
JNJ's Price/Owner Earnings (ttm) is ranked higher than
66% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.46 vs. JNJ: 22.31 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
JNJ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.19  Med: 17.52 Max: 25.26
Current: 22.31
10.19
25.26
P/B 4.27
JNJ's P/B is ranked lower than
69% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. JNJ: 4.27 )
Ranked among companies with meaningful P/B only.
JNJ' s P/B Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 4.99
Current: 4.27
2.68
4.99
P/S 4.46
JNJ's P/S is ranked lower than
64% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. JNJ: 4.46 )
Ranked among companies with meaningful P/S only.
JNJ' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 3.23 Max: 4.95
Current: 4.46
2.17
4.95
PFCF 23.80
JNJ's PFCF is ranked lower than
53% of the 200 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.43 vs. JNJ: 23.80 )
Ranked among companies with meaningful PFCF only.
JNJ' s PFCF Range Over the Past 10 Years
Min: 10.28  Med: 16.52 Max: 24.88
Current: 23.8
10.28
24.88
POCF 18.88
JNJ's POCF is ranked lower than
54% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.46 vs. JNJ: 18.88 )
Ranked among companies with meaningful POCF only.
JNJ' s POCF Range Over the Past 10 Years
Min: 8.98  Med: 13.18 Max: 19.85
Current: 18.88
8.98
19.85
EV-to-EBIT 14.88
JNJ's EV-to-EBIT is ranked higher than
68% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.56 vs. JNJ: 14.88 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.9 Max: 18.2
Current: 14.88
7.8
18.2
EV-to-EBITDA 12.54
JNJ's EV-to-EBITDA is ranked higher than
68% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.22 vs. JNJ: 12.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.9 Max: 14.8
Current: 12.54
6.7
14.8
PEG 3.42
JNJ's PEG is ranked lower than
66% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.91 vs. JNJ: 3.42 )
Ranked among companies with meaningful PEG only.
JNJ' s PEG Range Over the Past 10 Years
Min: 1.17  Med: 1.79 Max: 25.96
Current: 3.42
1.17
25.96
Shiller P/E 23.26
JNJ's Shiller P/E is ranked higher than
79% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.99 vs. JNJ: 23.26 )
Ranked among companies with meaningful Shiller P/E only.
JNJ' s Shiller P/E Range Over the Past 10 Years
Min: 15.52  Med: 20.88 Max: 28.71
Current: 23.26
15.52
28.71
Current Ratio 2.73
JNJ's Current Ratio is ranked higher than
56% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. JNJ: 2.73 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.08 Max: 3.08
Current: 2.73
1.2
3.08
Quick Ratio 2.36
JNJ's Quick Ratio is ranked higher than
61% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. JNJ: 2.36 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.72 Max: 2.68
Current: 2.36
0.94
2.68
Days Inventory 138.61
JNJ's Days Inventory is ranked lower than
61% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. JNJ: 138.61 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 105.89 Max: 137.6
Current: 138.61
100.19
137.6
Days Sales Outstanding 60.15
JNJ's Days Sales Outstanding is ranked higher than
65% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.25 vs. JNJ: 60.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.4
Current: 60.15
53.94
61.4
Days Payable 99.86
JNJ's Days Payable is ranked higher than
68% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.85 vs. JNJ: 99.86 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 99.86
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.76
JNJ's Dividend Yield is ranked higher than
74% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. JNJ: 2.76 )
Ranked among companies with meaningful Dividend Yield only.
JNJ' s Dividend Yield Range Over the Past 10 Years
Min: 2.05  Med: 2.84 Max: 3.84
Current: 2.76
2.05
3.84
Dividend Payout 0.54
JNJ's Dividend Payout is ranked lower than
71% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. JNJ: 0.54 )
Ranked among companies with meaningful Dividend Payout only.
JNJ' s Dividend Payout Range Over the Past 10 Years
Min: 0.39  Med: 0.47 Max: 0.65
Current: 0.54
0.39
0.65
Dividend Growth (3y) 7.10
JNJ's Dividend Growth (3y) is ranked lower than
53% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. JNJ: 7.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
JNJ' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7  Med: 13 Max: 17.1
Current: 7.1
7
17.1
Forward Dividend Yield 2.80
JNJ's Forward Dividend Yield is ranked higher than
70% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. JNJ: 2.80 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.86
JNJ's Yield on cost (5-Year) is ranked higher than
74% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. JNJ: 3.86 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
JNJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.88  Med: 4 Max: 5.39
Current: 3.86
2.88
5.39
3-Year Average Share Buyback Ratio 0.10
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. JNJ: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: -0.1 Max: 2.3
Current: 0.1
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.16
JNJ's Price/Tangible Book is ranked lower than
92% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. JNJ: 14.16 )
Ranked among companies with meaningful Price/Tangible Book only.
JNJ' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.24  Med: 10.44 Max: 18.92
Current: 14.16
6.24
18.92
Price/Projected FCF 1.60
JNJ's Price/Projected FCF is ranked higher than
70% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. JNJ: 1.60 )
Ranked among companies with meaningful Price/Projected FCF only.
JNJ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.86  Med: 1.4 Max: 3.6
Current: 1.6
0.86
3.6
Price/DCF (Earnings Based) 1.89
JNJ's Price/DCF (Earnings Based) is ranked lower than
66% of the 77 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. JNJ: 1.89 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.38
JNJ's Price/Median PS Value is ranked lower than
66% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. JNJ: 1.38 )
Ranked among companies with meaningful Price/Median PS Value only.
JNJ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.74  Med: 1.16 Max: 1.88
Current: 1.38
0.74
1.88
Price/Peter Lynch Fair Value 2.11
JNJ's Price/Peter Lynch Fair Value is ranked lower than
61% of the 150 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. JNJ: 2.11 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
JNJ' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.2  Med: 1.89 Max: 4.03
Current: 2.11
1.2
4.03
Price/Graham Number 3.57
JNJ's Price/Graham Number is ranked lower than
74% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.23 vs. JNJ: 3.57 )
Ranked among companies with meaningful Price/Graham Number only.
JNJ' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 3.19 Max: 5.97
Current: 3.57
1.97
5.97
Earnings Yield (Greenblatt) (%) 6.70
JNJ's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. JNJ: 6.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
JNJ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 5.5  Med: 7.7 Max: 12.9
Current: 6.7
5.5
12.9
Forward Rate of Return (Yacktman) (%) 13.91
JNJ's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.63 vs. JNJ: 13.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
JNJ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 13.7 Max: 18.6
Current: 13.91
1.8
18.6

More Statistics

Revenue (TTM) (Mil) $71,595
EPS (TTM) $ 5.65
Beta0.67
Short Percentage of Float0.74%
52-Week Range $94.28 - 126.07
Shares Outstanding (Mil)2,720.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 72,044 75,362 78,134
EPS ($) 6.65 7.17 7.55
EPS w/o NRI ($) 6.65 7.17 7.55
EPS Growth Rate
(3Y to 5Y Estimate)
4.25%
Dividends Per Share ($) 3.14 3.35 3.54
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
A Green Light on Bayer Jan 19 2017 
A Valuation of Johnson & Johnson Jan 17 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 
PPL Corp.: Geographically Diversified With 4.4% Yield, Long Dividend History Jan 12 2017 
Top 7 Dividend Health Care Stocks Jan 05 2017 
Kevin O’Leary’s Top 10 Quality Dividend Stocks Dec 29 2016 
US Market Indexes Higher for the Week Dec 24 2016 
Health Care Companies Showing Good Defensive Potential Dec 22 2016 
Donald Yacktman Reduces Multiple Positions in 3rd Quarter Dec 21 2016 
US Market Indexes Mixed on Monday Dec 12 2016 

More From Other Websites
Earnings Preview: What To Expect From Johnson & Johnson On Tuesday Jan 21 2017
Top 10 Multinational Corporations in the US Jan 20 2017
What Does Johnson & Johnson Predict for Its Medical Devices Segment? Jan 20 2017
Johnson & Johnson : JNJ-US: Dividend Analysis : November 22nd, 2016 (record date) : By the numbers :... Jan 20 2017
[$$] US stocks outlook: cloudy with meatloaves Jan 20 2017
How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16? Jan 20 2017
Johnson & Johnson's Ethicon Endo-Surgery to acquire medical device maker Megadyne Medical Products Jan 20 2017
8:32 am Johnson & Johnson's Ethicon acquires Megadyne Medical Products -- Complements and expands... Jan 20 2017
Ethicon Announces Acquisition of Megadyne Medical Products, Inc. Jan 20 2017
Why Johnson & Johnson’s 4Q16 Revenues Could Grow Jan 20 2017
Sanofi's M&A misses frustrate some investors in drugmaker Jan 20 2017
Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst Jan 19 2017
What to Expect from Johnson & Johnson’s 4Q16 Earnings Jan 19 2017
Low-Yield Dividend Stocks Belong in Your Portfolio Jan 19 2017
A Green Light on Bayer Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)